Literature DB >> 2971656

Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells.

K Keyomarsi1, R G Moran.   

Abstract

We have investigated the mechanism by which reduced folates, such as folinic acid, enhance the cytotoxicity of fluoropyrimidines in L1210 mouse leukemic cells. Exposure of L1210 cells to folinic acid resulted in expansion of intracellular pools of 5,10-CH2-H4PteGlun, delayed the reappearance of catalytically active thymidylate synthase (TS) following 5-fluoro-2'-deoxyuridine exposure, and stabilized inhibited TS complexes over the same concentration range that augmented the cytotoxic effects of fluorodeoxyuridine and 5-fluorouracil. The data showed that, in intact L1210 cells, fluorodeoxyridylate behaves as an inhibitor whose complexes with TS dissociated with a biologically significant rate. However, these complexes become functionally irreversible in cells incubated with high levels of folinic acid. It was also found that bound and total TS levels increased in cells treated with fluorodeoxyuridine to an extent that substantially exceeded the increase in protein content per cell under the same conditions. These results are in accord with the concept that folinic acid augments the effects of the fluoropyrimidines by expansion of cellular 5,10-CH2-H4PteGlun pools with subsequent stabilization of ternary complexes among 5-fluoro-2'-deoxyuridine 5'-monophosphate, TS, and 5,10-CH2-H4PteGlun. In light of the accumulation of TS that occurs following exposure to fluoropyrimidines, this stabilization may be needed for efficient tumor cell killing by these agents.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971656

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.

Authors:  N B Haas; R J Schilder; S Nash; L M Weiner; R C Catalano; R F Ozols; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

3.  Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells.

Authors:  P J Ferguson; O Collins; N M Dean; J DeMoor; C S Li; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

4.  Interaction between thymidylate synthase and its cognate mRNA in zebrafish embryos.

Authors:  Yuyan Zhang; Shaoli Yang; Ming Liu; Chunxia Song; Ning Wu; Peixue Ling; Edward Chu; Xiukun Lin
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

5.  Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.

Authors:  C Erlichman; B Mitrovski
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase.

Authors:  X Sun; A L Bognar; E N Baker; C A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

7.  Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.

Authors:  Jeng-Nian Yuan; Yee Chao; Wei-Ping Lee; Chung-Pin Li; Rheun-Chuan Lee; Full-Young Chang; Sang-Hue Yen; Shou-Dong Lee; Jacqueline Whang-Peng
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

8.  Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition.

Authors:  Alexandra C Racanelli; Scott B Rothbart; Cortney L Heyer; Richard G Moran
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

9.  Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.

Authors:  F H Valone; D R Gandara; J A Luce; S Wall; E A Perez; N Braham; M George; L Letvak
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.

Authors:  K H Chi; Y Chao; W K Chan; S S Lo; S Y Chen; S H Yen; K Y Chen; C W Wu; S D Lee; W Y Lui
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.